1. Introduction {#s0005}
===============

Coronavirus is one of the major viruses that primarily targets the human respiratory system, but it also has neuroinvasive capabilities and can spread from the respiratory tract to the central nervous system (CNS). Previous epidemics or pandemics of coronaviruses include the severe acute respiratory syndrome (SARS) in 2002 and the Middle East respiratory syndrome (MERS) in 2012. The most recent pandemic of coronavirus infection is coronavirus disease (COVID-19) that is caused by SARS-CoV2 \[[@bb0005],[@bb0010]\]. The symptoms of COVID-19 infection usually appear after an incubation period of about five days. The most common symptoms of COVID-19 illness are fever, cough, and fatigue; other symptoms include headache, hemoptysis, and dyspnea, among others. In the most severe cases, patients may develop pneumonia, acute respiratory distress syndrome, acute cardiac problems, and multiorgan failure \[[@bb0005]\]. The first cases of COVID-19 were reported in December 2019 \[[@bb0005]\]; however, when we searched the MEDLINE (accessed from PubMed), from December 01, 2019 to March 26, 2020, with the key word "COVID 19", surprisingly 1655 articles were yielded. This shows that COVID-19 pandemic is of great global public health concern.

Coronavirus infections have been associated with neurological manifestations (e.g., febrile seizures, convulsions, change in mental status, and encephalitis) \[[@bb0010],[@bb0015]\]. Neurotropic and neuroinvasive capabilities of coronaviruses have been described in humans. Upon nasal infection, coronavirus enters the CNS through the olfactory bulb, causing inflammation and demyelination \[[@bb0015]\]. In this systematic review, we will discuss the evidence on the occurrence of CNS involvement and neurological manifestations in patients with COVID-19.

2. Methods {#s0010}
==========

The report of this systematic review was made according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@bb0020],[@bb0025]\] ([Fig. 1](#f0005){ref-type="fig"} ). The review protocol was not previously registered. MEDLINE (accessed from PubMed) and Scopus from December 01, 2019 to March 26, 2020 were systematically searched for related published articles. In both electronic databases, the following search strategy was implemented and these key words (in the title/abstract) were used: "COVID 19" OR "coronavirus" AND "brain" OR "CNS" OR "neurologic". Articles written in English were all included in this search. To ensure literature saturation, the authors scanned the reference lists of the included studies or relevant reviews identified through the search. Both authors participated through each phase of the review independently (screening, eligibility, and inclusion). They independently screened the titles and abstracts yielded by the search against the inclusion criteria. They obtained full reports for all titles that appeared to meet the inclusion criteria or where there was any uncertainty. Authors screened the full text reports and decided whether these meet the inclusion criteria. They resolved any disagreement through discussions. Neither of the authors were blind to the journal titles or to the study authors or institutions.Fig. 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram of the study.Fig. 1

The following data were extracted from the included studies: study authors, study designs, main results, and limitations. The methodological quality of the included studies was assessed by the authors. The class of evidence was defined following the American Academy of Neurology criteria for classification of evidence in studies of causation (Appendix 1) \[[@bb0030]\].

2.1. Standard protocol approvals, registrations, and patient consents {#s0015}
---------------------------------------------------------------------

The Shiraz University of Medical Sciences Institutional Review Board approved this systematic review.

3. Results {#s0020}
==========

Through the search strategy, we could identify two articles about neurological involvement by COVID-19 ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} ) \[[@bb0035],[@bb0040]\]. One of these publications was a narrative review \[[@bb0035]\] and the other one was a viewpoint \[[@bb0040]\]. However, to ensure literature saturation, the authors scanned the reference lists of the included studies and could identify multiple references \[9--14\]. [Table 3](#t0015){ref-type="table"} shows the summary of these studies on the CNS manifestations of COVID-19. One study, specifically investigated the neurological manifestations of COVID-19 and could document CNS manifestations in 25% of the patients \[[@bb0045]\]. However, the authors did not perform electroencephalography (EEG) or cerebrospinal fluid (CSF) analysis. Another retrospective study investigated acute cerebrovascular disease occurrence following COVID-19 \[[@bb0050]\]. Other studies investigated the manifestations of COVID-19 in general; they did not specifically pay attention to the neurological manifestations \[[@bb0055], [@bb0060], [@bb0065], [@bb0070]\].Table 1The search keywords included "COVID 19" and those in the first column of the table.Table 1Medline (PubMed)Scopus (Article title, Abstract, Keywords)KeywordsPrimary hintsRelevant articlesPrimary hintsRelevant articlesBrain17021 (duplicate)Neurologic1111 (duplicate)CNS1100**Total19232 (2 duplicates)**Table 2The search keywords included "coronavirus" and those in the first column of the table.Table 2Medline (PubMed)Scopus (Article title, Abstract, Keywords)KeywordsPrimary hintsRelevant articlesPrimary hintsRelevant articlesBrain222 (2 duplicates)91 (duplicate)Neurologic11 (duplicate)41 (duplicate)CNS41 (duplicate)30**Total274 (4 duplicates)162 (2 duplicates)**Table 3Neurological manifestations of COVID-19.Table 3Author/yearMethodsNeurological manifestationsLimitationsLevel of evidenceMao/ 2020 \[[@bb0045]\]Retrospective case series of 214 admitted patientsCNS manifestations: in 25%. Headache (13%), dizziness (17%), impaired consciousness (8%), acute cerebrovascular problems (3%), ataxia (0.5), and seizures (0.5%)No CSF analysis; no EEG study; no clear definition of symptomsIIILi/ 2020 \[[@bb0050]\]Retrospective case series of 221 admitted patients5% developed acute ischemic stroke, 0.5% had cerebral venous sinus thrombosis, and 0.5% had cerebral hemorrhageOther related neurological manifestations were not studied.IIHuang/ 2020 \[[@bb0055]\]Prospective study of 41 admitted patientsHeadache in 8%Not specifically studied neurological manifestations. No CSF or EEG studiesIYang/ 2020 \[[@bb0060]\]Retrospective study of 52 critically ill adult patientsHeadache in 6%Not specifically studied neurological manifestations. No CSF or EEG studiesIIWang/ 2020 \[[@bb0065]\]Retrospective case series of the 138 hospitalized patientsDizziness in 9%; Headache in 7%Not specifically studied neurological manifestations. No CSF or EEG studiesIIChen/ 2020 \[[@bb0070]\]Retrospective case series of the 99 hospitalized patientsConfusion in 9%; Headache in 8%Not specifically studied neurological manifestations. No CSF or EEG studiesII[^1]

4. Discussion {#s0025}
=============

In this study, we observed that the evidence on the CNS involvement and neurological manifestations of COVID-19 is scarce and of low quality. However, the only study that specifically investigated this issue documented that one-quarter of the hospitalized patients with a confirmed diagnosis of severe acute respiratory syndrome from coronavirus 2 infection had some manifestations of CNS involvement \[[@bb0045]\]. Some patients with COVID-19 may show nonspecific neurological symptoms, such as confusion and headache. A few patients with COVID-19 showed more specific neurological manifestations, such as seizure or cerebrovascular problems ([Table 3](#t0015){ref-type="table"}). Furthermore, neuroinvasion of SARS-CoV2 may partially explain why some patients develop respiratory failure, while others do not \[[@bb0035]\].

Most coronaviruses share similar viral structures and infection pathways; hence, the pathomechanisms previously found for other coronaviruses may also be applicable for SARS-CoV2. Human coronaviruses are not always confined to the respiratory tract; they can invade the CNS. A growing body of evidence shows that neuroinvasion and neurotropism is a common feature of human coronaviruses \[[@bb0010]\]. Infection with SARS-CoV has been associated with neurological manifestations. In the reported patients with SARS-CoV, CSF tested positive for the virus \[[@bb0075],[@bb0080]\]. In one study of 183 hospitalized children with clinically suspected acute encephalitis, 22 (12%) had coronavirus infection (type was not specified) by detection of anti-CoV IgM \[[@bb0085]\]. In a study of 70 patients with MERS-CoV infection, altered mental status was reported in 26% of the patients and 9% of the people had seizure \[[@bb0090]\]. Therefore, it is very likely to observe neurological manifestations in patients with COVID-19 if we carefully and specifically look for them.

Finally, patients with severe COVID-19 may have hypoxia, multiorgan failure, and metabolic and electrolyte derangements, and may require sophisticated medication regimens and therapeutic interventions. Hence, it is plausible to expect clinical or subclinical acute symptomatic seizures and status epilepticus to happen in these patients. Impaired mental status has been reported in patients with severe COVID-19 \[9, 14\]; but, this manifestation has never been studied appropriately in previous studies ([Table 3](#t0015){ref-type="table"}). When visiting a patient who is in a critical medical condition and has a change in mental status, one should make sure that nonconvulsive status epilepticus (NCSE) is not a part of the clinical scenario. The diagnosis of NCSE is frequently overlooked, with patients in critical medical conditions having other serious problems. It is necessary to perform continuous EEG monitoring in any patient with a critical medical condition, who has a change in mental status, in order to make a timely diagnosis of NCSE \[[@bb0095]\]. Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus is a helpful guide to make a diagnosis of NCSE in critically ill patients \[[@bb0100]\].

5. Conclusion {#s0030}
=============

While neurological manifestations of COVID-19 have not been studied appropriately yet, it is highly likely that some of these patients, particularly those who suffer from a severe illness, have CNS involvement and neurological manifestations. Precise and targeted documentation of the neurological symptoms (e.g., headache, dizziness, etc.) and signs (e.g., change in mental status, meningeal signs, etc.), detailed clinical, neurological, and electrophysiological investigations (e.g., EEG) of the patients (particularly those with a change in mental status), attempts to isolate SARS-CoV-2 from CSF, and autopsies of the COVID-19 victims may clarify the roles played by this virus in causing neurological manifestations.
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[^1]: CNS: central nervous system; CSF: cerebrospinal fluid; EEG: electroencephalography.
